A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)

Inclusion Criteria: \- Must have a positive serology result for Trypanosoma cruzi on any 2 of 3 of the following tests: indirect immunofluorescence, indirect hemagglutination, or enzyme-linked immunoabsorbent assay (ELISA) * Must have a positive qualitative polymerase chain reaction (PCR) for Trypanosoma cruzi * Must have a normal 12-lead electrocardiogram (ECG) * Must have a normal 2-D echocardiogram * Must have no evidence of ventricular tachycardia on 24-hour Holter monitoring * Female participants of childbearing age must be using a medically accepted method of birth control before beginning study drug treatment and must agree to continue its use during the study, or must have been surgically sterilized * Female participants of childbearing potential must have a negative serum beta-human chorionic gonadotropin (hCG) pregnancy test at Screening and a negative urine pregnancy test at Baseline or within 72 hours before the start of study drug Exclusion Criteria: * Are breastfeeding, pregnant, or planning to become pregnant * Body weight \<60 kg * Have an immunodeficiency or are immunosuppressed * History of megacolon with obstipation or megaesophagus with severe swallowing impairment. * Have previously received treatment with benznidazole or nifurtimox * Known allergy/sensitivity to azoles * Has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 2.5 times the upper limit of normal at Screening * Has serum creatinine \>2.5 mg/dL or 200 micromoles at Screening * Has a history of severe alcohol abuse within two years from Screening * Is taking any of the prohibited medication